Home Tags Regeneron Pharmaceuticals

Tag: Regeneron Pharmaceuticals

Westchester IDA hears $480M Regeneron proposal

Regeneron Pharmaceuticals wants to build a $480 million pre-clinical manufacturing and process development facility in Greenburgh.

Nine Fairfield, four Westchester firms make Fortune 500

IBM led the way in Westchester, while Charter Communications was the top-ranked firm in Fairfield County.

IBM leads Westchester County companies on Fortune 500

The Armonk company’s new ranking was reflective of its 4 percent revenue growth in the fourth quarter of 2017, the first increase after 22 consecutive quarters of decline.

Regeneron, Sanofi will invest $2B for new cancer drugs

The global collaboration partners aim to discover, develop and market new drug treatments in the emerging field of immuno-oncology.

Regeneron’s cholesterol-lowering drug approved by FDA

The Food and Drug Administration approves the use of Praluent, developed by Regeneron Pharmaceuticals in Westchester and its French collaborator Sanofi.

Regeneron pays $73M for vacant land for future growth

The biotech company becomes a Westchester County landowner with its recent purchase of undeveloped property near its Eastview headquarters.

Regeneron genetics research shapes future of medical care

The year-old Regeneron Genetics Center is sequencing genetic samples from a quarter of a million Pennsylvanians as a pioneer of precision medicine.

Regeneron announces Q4 earnings

The Greenburgh biotech company announces sales of its drug Eylea rose 39 percent in the fourth quarter.

Investing in Westchester’s biotech surge

Companies like Regeneron and Acorda – and their investors – hope to make a profit, but how does an investor get in on Westchester County’s biotech boom?

Westchester biotech companies report strong quarters

Acorda Therapeutics posts earnings well above Wall Street expectations, while Regeneron and Progenics also post a profit.

Science magazine: Regeneron top biopharmaceutical employer

The Greenburgh company has been recognized by Science magazine as the top biopharmaceutical employer in the world for the third year in a row.

Regeneron Genetics Center adds research partners

The Regeneron Pharamceuticals Inc. subsidiary will collaborate with three institutions on family-based genetics research.

Progenics, Regeneron announce positive product news

Regeneron announces positive study results for a sinus drug, and Progenics' drug Relistor gains another approved use by the U.S. Food and Drug Administration.

Regeneron eye drug tabbed ‘breakthrough therapy’ by FDA

Federal officials have designated Regeneron's Eylea drug a breakthrough therapy for diabetic patients with retinal damage.

Regeneron anti-cholesterol drug effective in clinical trials

The Greenburgh-based pharmaceutical company announces its drug alirocumab reduced levels of “bad cholesterol” by 61 percent in a study.